Egfr-targeted therapy for non-small cell lun cancer: Focus on EGFR oncogenic mutation

Alberto Antonicelli, Stefano Cafarotti, Alice Indini, Alessio Galli, Andrea Russo, Alfredo Cesario, Filippo Maria Lococo, Patrizia Russo, Alberto Franco Mainini, Luca Giuseppe Bonifati, Mario Nosotti, Luigi Santambrogio, Stefano Margaritora, Pierluigi Maria Granone, André Emanuel Dutly

Research output: Contribution to journalArticle

Abstract

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs). This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient- tailored therapy could be closer than commonly expected.

Original languageEnglish
Pages (from-to)320-330
Number of pages11
JournalInternational Journal of Medical Sciences
Volume10
Issue number3
DOIs
Publication statusPublished - Feb 11 2013

Keywords

  • Advanced
  • EGFR targeted therapy
  • Mutation
  • NSCLC
  • Resistance
  • TKIs

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Egfr-targeted therapy for non-small cell lun cancer: Focus on EGFR oncogenic mutation'. Together they form a unique fingerprint.

  • Cite this

    Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F. M., Russo, P., Mainini, A. F., Bonifati, L. G., Nosotti, M., Santambrogio, L., Margaritora, S., Granone, P. M., & Dutly, A. E. (2013). Egfr-targeted therapy for non-small cell lun cancer: Focus on EGFR oncogenic mutation. International Journal of Medical Sciences, 10(3), 320-330. https://doi.org/10.7150/ijms.4609